ACE2 News and Research

RSS

Interfering RNA nanoparticles could be a potential COVID-19 therapy

Study shows lipid nanoparticle-based siRNA is potent in suppressing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the causative agent of coronavirus disease 2019 (COVID-19) – in cells as well as in mice models.

21 Apr 2021

What do we know about the origin and evolution of SARS-CoV-2?

A new study examines the origin and continuing evolution of SARS-CoV-2 in the human and animal co-hosts in an attempt to help prepare for future destructive outbreaks.

21 Apr 2021

Immune escape by SARS-CoV-2 mutations acquired in mink

A new study, published in Cell Reports, suggests that SARS-CoV-2 may have acquired such immune evasion mutations during its transmission in farmed mink.

21 Apr 2021

Researchers explore cost-effective identification method for novel SARS-CoV-2 variants

In a new study, a rapid and cost-effective method of detecting known variants of concern has been developed utilizing capillary electrophoresis, allowing local facilities to screen for and track SARS-CoV-2 variants of concern and implement reactionary procedures.

21 Apr 2021

Researchers examine antiviral responses in children infected with COVID-19 in South Brazil

New research has been published that focuses on the characterization of innate and adaptive immune responses in adult patients with different degrees of severity and also in pediatric patients with mild symptoms of COVID-19. In this study, researchers have developed an immune profile in children to understand the difference in COVID-19 infection in children and adults.

21 Apr 2021

Antibody response induced by mRNA vaccination differs from natural SARS-CoV-2 infection

Researchers tested the antibodies elicited from mRNA vaccination and compared them to those from natural SARS-CoV-2 infection. They found the vaccine did not have antibodies to the virus nucleocapsid protein but had potent RBD antibodies.

21 Apr 2021

Characterization of lab-produced neutralizing antibodies targeting SARS-CoV-2

A new study led by Hans-Martin Jäck of the Friedrich-Alexander University Erlangen-Nuremberg in Germany engineered clusters of neutralizing monoclonal antibodies using a transgenic mouse model. A unique characteristic for the antibodies was the different ways it bound to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the overall reduction in the viral spread for human ACE2.

21 Apr 2021

Study identifies how SARS-CoV-2 enters and infects the brain

A recent preclinical study led by Anja Kipar of the University of Zurich and the University of Liverpool found evidence of the virus infecting and eventually provoking cell death in microglia and immune cells — but not neurons. The viral-induced apoptosis in these brain cells may explain why some long-haulers experience ‘brain fog’ months after recovery.

21 Apr 2021

Can an immunosuppressive cancer drug promote SARS-CoV-2 entry into host cells?

A new study shows that rapamycin, an immunosuppressive drug used in some cancers, and its analogs, may have an undesirable effect on viral entry into the host cells. This finding could inform their use to treat symptomatic COVID-19.

20 Apr 2021

Humoral immunity developed by DNA vaccine INO-4800 is effective against SARS-CoV-2 variants

A team of international scientists recently demonstrated that antibodies generated in response to the DNA vaccine INO-4800 can effectively neutralize some of the recently emerged variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), such as G614, 501Y.V1, and 501Y.V2.

20 Apr 2021

Screening drug candidates for COVID-19 treatment using computational methods

Researchers identified two potential drug candidates that can inhibit SARS-CoV-2 in vitro. Their combination can work synergistically and increase their inhibitory effect.

19 Apr 2021

Researchers develop computational model to predict changes in SARS-CoV-2’s viral fitness

Two researchers from the Université Libre de Bruxelles in Belgium, Fabrizio Pucci and Marianne Rooman, recently built a simplified computational model, called SpikePro, to predict the SARS-CoV-2 fitness from the amino acid sequence and structure of the spike protein. This study focuses on the spike protein’s stability and the binding affinity to the host receptor.

19 Apr 2021

Could a tuna-derived protein inhibit SARS-CoV-2?

A recent study in the journal Food Chemistry draws attention to the need for finding nutritional supplements with potential SARS-CoV-2 inhibition effects in the wake of the COVID-19 pandemic.

19 Apr 2021

Plant-derived compound isorhamnetin may have antiviral potential against SARS-CoV-2

The lack of new or repurposed drugs to treat patients with severe or critical COVID-19 has been one of the biggest hurdles to reducing mortality rates in the ongoing pandemic caused by SARS-CoV-2. A new study describes the potential for the use of the plant molecule isorhamnetin in the management of this virus.

19 Apr 2021

Humans versus viruses - Can we avoid extinction in near future?

Expert argues that human-caused changes to the environment can lead to the emergence of pathogens, not only from outside but also from our own microbiome, which can pave the way for large-scale destruction of humans and even our extinction.

19 Apr 2021

Novel mRNA delivery vehicle provides alternative to LNPs for SARS-CoV-2 vaccines

Researchers in the United States have developed an alternative messenger RNA (mRNA) delivery platform to the lipid nanoparticles that are currently used in vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

18 Apr 2021

SARS-CoV-2 can alter bone marrow macrophage (BMM)-to-osteoclast differentiation, study finds

Now, a team of researchers in China and Australia has shown that SARS-CoV-2 infection can affect bone marrow macrophage (BMM)-to-osteoclast differentiation, which may impact the skeletal system.

16 Apr 2021

Curcumin nanosystems could be powerful COVID-19 therapeutics

With new variants of SARS-CoV-2 emerging, the COVID-19 pandemic is far from over. While the global vaccine rollout has moved at an impressive speed, the search for new safe, effective, and targeted therapies is still on. Now, a new study reviews the potential for curcumin, a natural alkaloid derived from turmeric, and nanosystems to treat COVID-19.

16 Apr 2021

Researchers probe intriguing interaction between sugars and the SARS-CoV-2 spike protein

A new study posted to the bioRxiv preprint server focuses on a novel formulation of magnetization or saturation transfer. This method is developed by amalgamating theoretical and computational approaches based on a Bayesian deconvolution algorithm, which helps obtain data more accurately and determine the ligand-protein interaction.

16 Apr 2021

Modeling study suggests how different SARS-CoV-2 mutations prevent antibody binding

This suggests a cocktail of antibodies will work better at neutralizing the virus than a single antibody alone. In a study published in the bioRxiv* preprint server, researchers report the structure of binding complexes of the different classes of antibodies to the spike RBD using computational modeling, which may also help explain how the virus generates escape mutations.

16 Apr 2021

ACE2 News and Research

Interfering RNA nanoparticles could be a potential COVID-19 therapy

What do we know about the origin and evolution of SARS-CoV-2?

Immune escape by SARS-CoV-2 mutations acquired in mink

Researchers explore cost-effective identification method for novel SARS-CoV-2 variants

Researchers examine antiviral responses in children infected with COVID-19 in South Brazil

Antibody response induced by mRNA vaccination differs from natural SARS-CoV-2 infection

Characterization of lab-produced neutralizing antibodies targeting SARS-CoV-2

Study identifies how SARS-CoV-2 enters and infects the brain

Can an immunosuppressive cancer drug promote SARS-CoV-2 entry into host cells?

Humoral immunity developed by DNA vaccine INO-4800 is effective against SARS-CoV-2 variants

Screening drug candidates for COVID-19 treatment using computational methods

Researchers develop computational model to predict changes in SARS-CoV-2’s viral fitness

Could a tuna-derived protein inhibit SARS-CoV-2?

Plant-derived compound isorhamnetin may have antiviral potential against SARS-CoV-2

Humans versus viruses - Can we avoid extinction in near future?

Novel mRNA delivery vehicle provides alternative to LNPs for SARS-CoV-2 vaccines

SARS-CoV-2 can alter bone marrow macrophage (BMM)-to-osteoclast differentiation, study finds

Curcumin nanosystems could be powerful COVID-19 therapeutics

Researchers probe intriguing interaction between sugars and the SARS-CoV-2 spike protein

Modeling study suggests how different SARS-CoV-2 mutations prevent antibody binding

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News